Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Company Deals

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

Fineline Cube May 21, 2026
Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Fineline Cube May 21, 2026
Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Fineline Cube May 21, 2026
Company Drug

Shanghai Ark Biopharmaceutical’s AK0901 Meets Phase III Endpoints in ADHD Trial

Fineline Cube Mar 25, 2025

China’s Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study...

Company

WuXi XDC Reports 90.8% Revenue Surge, Expanding in ADC Market

Fineline Cube Mar 25, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...

Company Drug

Suzhou Xueji Biotech’s XJ-MK-002 Gets FDA Orphan Drug Designation for CAMT

Fineline Cube Mar 25, 2025

China-based cell therapy developer Suzhou Xueji Biotechnology Co., Ltd’s (HemaCell) XJ-MK-002, described as the world’s...

Company Drug

Beijing Sungen Biomedical’s SGC001 Receives FDA Fast Track Designation for AMI Treatment

Fineline Cube Mar 25, 2025

China-based Beijing Sungen Biomedical Technology Co., Ltd, an antibody developer incubated by Hotgen Biotech Co.,...

Company Deals

CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China

Fineline Cube Mar 25, 2025

Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an...

Company Drug

AllianThera Biopharma Starts Global Phase I Trial for ATB102 in Inflammatory Bowel Diseases

Fineline Cube Mar 24, 2025

Suzhou-based startup AllianThera Biopharma has announced the first patient dosing in a global Phase I...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Ivarmacitinib Receives NMPA Approval for Ankylosing Spondylitis

Fineline Cube Mar 24, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving marketing approval from the National...

Company Medical Device

Oriomics’ Liver Cancer Screening Reagent Earns FDA Breakthrough Device Designation

Fineline Cube Mar 24, 2025

Hangzhou-based Oriomics, a cancer screening specialist backed by Hotgen Biotech Co., Ltd (SHA: 688068), has...

Company Deals Drug

Kexing Biopharm Partners with BioMap on AI-Driven Macromolecular Drug Development

Fineline Cube Mar 24, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with US biotech firm BioMap...

Company Drug

CStone Pharmaceuticals Files for EMA Approval of Sugemalimab for Unresectable Stage III NSCLC

Fineline Cube Mar 24, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced filing for another indication approval for its anti-programmed...

Company Deals

Abbisko Therapeutics and Allist Pharmaceuticals Partner on KRAS-G12C NSCLC Combination Therapy

Fineline Cube Mar 24, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has entered into a cooperation agreement with...

Company

Eli Lilly Launches Lilly Gateway Laboratory in China to Boost Biotech Innovation

Fineline Cube Mar 24, 2025

US major Eli Lilly & Co., (NYSE: LLY) has announced the opening of the Lilly...

Company Drug

Clover Biopharmaceuticals Receives FDA Approval for SCB-1019 RSV Vaccine Trial

Fineline Cube Mar 24, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced receiving clinical approval from the US Food...

Company Drug

AIM Vaccine’s mRNA-based Shingles Vaccine Receives FDA Approval for Clinical Study

Fineline Cube Mar 24, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the US Food...

Medical Device Policy / Regulatory

NMPA Updates Rules on Domestic Production of Imported Medical Devices

Fineline Cube Mar 24, 2025

The National Medical Products Administration (NMPA) has released a notification on further adjusting and optimizing...

Company Medical Device

Broncus Medical’s BroncQCT Approved by Zhejiang Administration for China Market Entry

Fineline Cube Mar 24, 2025

Broncus Medical Inc., a provider of precision intervention solutions for lung diseases with operations in...

Company Medical Device

Lifetech Scientific’s LAmbre Plus LAA Closure System Gains US Medical Insurance Coverage

Fineline Cube Mar 24, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) has announced obtaining medical insurance coverage in the United...

Company

Hansoh Pharmaceutical Reports 21% Revenue Growth, Boosted by Innovative Drugs

Fineline Cube Mar 24, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) released its 2024 financial report last week,...

Company

Johnson & Johnson Pledges USD55 Billion for US Expansion, Focusing on Manufacturing and R&D

Fineline Cube Mar 24, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55...

Company Drug

FDA Issues Second CRL to Hengrui’s Camrelizumab Combo Due to Manufacturing Issues

Fineline Cube Mar 24, 2025

The US Food and Drug Administration (FDA) last week issued another complete response letter (CRL)...

Posts pagination

1 … 194 195 196 … 669

Recent updates

  • Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate
  • Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
  • Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
  • Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
  • Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.